Articles Comments

Health and Diseases » Archive

More useless evidence of statin drug Simvastatin combined with interferon beta for MS patients

Since linked to increased muscle injury risk and recently the U.S. Food and Drug Administration (FDA) warned doctors to limit the usage of Simvastatin 80 mg to their patients who have taking it for a year and not used in new patients, recent large trials of SIMCOMBIN led by Per Soelberg Sorensen, MD, from Copenhagen University Hospital in Denmark reported that combination of Simvastatin and interferon beta have no benefit compared to other statins for relapsing-remitting Multiple Sclerosis (MS). Although the adverse events found in the study categorized as mild and almost similar in placebo group, such as infections or muscoloskeletal disorders, myalgia, rhabdomyolysis, and myoglobinuria, the authors warned to be careful and ‘think twice’ if treatment for MS combined with statin drugs in general, particularly with Simvastatin. It says so, because … Read entire article »

Filed under: Multiple Sclerosis

PPIs discontinuation after erosive esopaghitis therapy won’t cause heartburn again or even worse

Previous studies said that increased excessive acid secretion through indicator of Gastrin levels which may cause Heartburn can re-occur if the use of proton pump inhibitors (PPIs) discontinued in the patients who already have erosive esopaghitis therapy, including can cause acid-related symptoms if stopped for a while. However, from recent study conducted by researchers from the University of Pennsylvania said that the effects doesn’t like that. According to current study authors, increased gastrin levels after PPIs discontinuation will return to normal within a month and remain flat thereafter. The results of this study were reported in the American Journal of Gastroenterology on August 16, 2011, and based on reviewed data from 4 phase III trials involved 287 patients with a negative indication for Helicobacter pylori. While there is no long run of increased gastrin … Read entire article »

Filed under: Stomach ache

Ovarian cancer risk and mesothelin (MSLN) antigen levels

Until now, early detection of ovarian cancer risk still see many obstacles, making it difficult for physicians to perform preventive treatment to suspected patients. The impact of all this, the risk of death from ovarian cancer is quite high. However, from a recent findings that published in Cancer Epidemiology, Biomarkers & Prevention on August 16, 2011, the researchers found that mesothelin (MSLN), a 40kDa protein that form a tumor in mesothelial cells, could be a biormarker of ovarian cancer occurrence. Although the findings require additional research to find out more, but this discovery could help the health practitioners to give more attention to their patients who had experienced with premature ovarian failure and/or a reduction on ovarian function to the risk of ovarian cancer. According to study authors, in women with prematurely reduced … Read entire article »

Filed under: Vagina

Androgen deprivation therapy (ADT) may not increased cardiovascular mortality risk

Some previous reports mentioned that the prostate cancer treatment with androgen deprivation therapy (ADT) associated with cardiovascular toxicity. However, most of studies have been retrospective, while in an analyses of clinical trials randomizing to ADT or no-ADT were likely find nothing increased cardiac mortality risk. Therefore, to investigate more detail about the relationship between ADT and cardiovascular mortality, the researchers assessed mortality outcomes in 7,248 men in the CaPSURE registry. Among participants, 5,170 men (71.3%) have local treatment, 1,087 men (6.7%) have primary ADT, 484 men (6.7%) have both local treatment plus ADT, and 506 men (7.0%) in watchful waiting/active surveillance (WW/AS). Reported in the Journal of Clinical Oncology on August 15, 2011, the researchers from University of California, San Fransico, said that ADT may not increase the risk of cardiovascular mortality. Although there were … Read entire article »

Filed under: Prostate Cancer

Rivaroxaban not superior to warfarin in preventing stroke and major embolism in AF patients

While previous scientific session at the American Heart Association (AHA) in 2010 showed that Rivaroxaban (Xarelto, Bayer/Johnson & Johnson) was not superior to Warfarin in preventing stroke and non-central nervous system (CNS) embolism in patients with atrial fibrillation (AF), currently the researchers concluded that this oral anticoagulant really not superior to warfarin on major embolism and stroke prevention for AF patients. However, this drug showed better in patients treated only with the drug in an on-treatment comparison which is significantly showed reduced the risk of stroke and non-CNS embolization 21% compared with warfarin. This conclusion based on ROCKET-AF trial led by Dr. Manesh Patel from Duke Clinical Research Institute, Durham, NC. The trial involved 14,264 patients with nonvalvular atrial fibrillation who were at an increased risk of stroke, such as those with prior … Read entire article »

Filed under: Atrial Fibrillation

Obstructive sleep apnea (OSA) treatment with compression stockings

Previous studies have suggested that the volume of fluid shifting from the legs into the neck overnight plays a pathophysiological role in obstructive sleep apnea (OSA). Since compression stockings are designed to remedy impaired musculovenous pump performance due to incompetent leg vein valves, recent study found that wearing compression stockings during the day in nonobese individual with OSA and venous insufficiency showed debilitates OSA. This is indicated by the reduced accumulation of fluid in the leg and redistribution overnight to the neck. Therefore, reducing overnight rostral fluiod displacement means it can smooth the OSA symptoms. This findings appeared in the American Journal of Respiratory and Critical Care Medicine on August 4, 2011. According to the study authors, Stefania Redolfi, MD, from the University of Brescia in Italy together with French researchers said that their study … Read entire article »

Filed under: Obstructive Sleep Apnea

Adding Imiquimod (Aldara) to standard cervical dysplasia treatment won’t prevent its recurrence

Immunomodulator medication which has the active ingredient of imiquimod (INN) has been approved by the FDA to treat premalignant of skin, cutaneous condition of subtype of basal cell carcinoma, and external genital warts with the side effects that should be considered. Due to genital warts, this drug may enhance the immune response, the researchers hypothesized that when adding this drug to current standard cervical dysplasia treatment (freezing, electrosurgery, or scalpels) may help from its recurring. However, after 2 years of randomized trial in 56 women with cervical dysplasia, which half of them also received topical imiquimod (Aldara) over roughly two weeks, the researchers said that imiquimod no help in preventing from recurrence. While 4 women in both of groups showed recurrence that involved at least one HPV type matching the type present at … Read entire article »

Filed under: Cervical Dysplasia

Iliac vein stenosis increases left-sided deep vein thrombosis (DVT) risk in women used combined oral contraceptive (COC)

Up to 25% of people in the healthy population have underlying stenosis for greater than 50% of the left common iliac vein. However, for women who have significant venous stenosis of the common iliac vein, who also use combined oral contraceptives (COC), they are at higher risk of deep vein thrombosis (DVT) than average risk. According to recent findings, every 1% increase in iliac vein stenosis (greater than 70%) increased the risk of DVT by 5%. And those who also use COC, the odds ratio of DVT increase to 5.46% for every 1% increase in stenosis. This conclusion based on evaluated 35 DVT’s women with computed tomography or magnetic resonance imaging and 35 age-matched control women who presented to the emergency room with abdominal pain. Reported in the American Journal of Obstetrics and Gynecology … Read entire article »

Filed under: Thrombosis

High dose antipsychotics Quetiapine no help in improving schizophrenia symptoms

Quetiapine is an antipsychotic drug for patients with schizophrenia or bipolar disorder. However, these drugs often used in high dose without adequate supporting data from the benefits of such action. While the use of quetiapine should be discontinued gradually and provide some potential side effects, the benefits of high doses also not useful in improving schizophrenia symptoms. In fact, the patient’s weight tend to rise. This conclusion is obtained after the researchers conducted a randomized trial for patients receiving approved-dose (800 mg/day) as a placebo group (43 patients) and a group with higher dose of 1,144 mg/day (88 patients). The improvement of schizophrenia symptoms measured with Positive and Negative Syndrome Scale (PANSS) score after treatment. Reported in the Journal of Clinical Psychiatry on June 14, 2011, the study authors, Dr. William G. Honer from the … Read entire article »

Filed under: Schizophrenia and Bipolar Disorder

Skin toxicities risk from hydroxyure (HU) treatment in patients with myleoproliferative neoplasm (MPN)

Patients with high risk of abnormal new growth of tissue or may be a tumour from their bone marrow disease (known as myeloproliferative neoplasm, MPN) are often and have long been receiving treatment with antineoplastic drug to suppresses the production of blood cell precursor in the bone marrow. However, this drug (known as hydroxyurea, HU) seem causing toxicities in the skin. This is based on studied among 993 patients registered between 1980 and 2009, including 614 (61.8) who received HU from four different hematologic centers for Philadelphia chromosome-negative MPN patients. According to the study authors, Dr. Roberto Latagliata from La Sapienza University in Rome and colleagues said that their findings showed the severe and frequent of skin toxicity during HU treatment no longer categorized as ‘mild’ like it was believed for decades from … Read entire article »

Filed under: Myeloproliferative